TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34991692

Group type: EXPERIMENTAL
Intervention: Seated social breaks
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Simple resistance activities
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Step-up activities
Number of subjects: 16
Study: 34991701

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) and two mobile health (mHealth) components: oral health promotion messages and storytelling videos delivered using WhatsApp messenger
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention applied)
Number of subjects: 0
Study: 34991703

Group type: EXPERIMENTAL
Intervention: 10 mg oral montelukast every 24 hours
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34991704

Group type: EXPERIMENTAL
Intervention: Azithromycin mass drug administration (MDA)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 34991708

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus azacitidine
Number of subjects: 30
Study: 34991824

Group type: EXPERIMENTAL
Intervention: Post-PCI iFR ≥0.95
Number of subjects: 500

Group type: COMPARATOR
Intervention: Post-PCI iFR <0.95
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Post-PCI iFR ≥0.95 in highly symptomatic patients (baseline SAQ-AF score ≤60)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Post-PCI iFR <0.95 in highly symptomatic patients (baseline SAQ-AF score ≤60)
Number of subjects: 500
Study: 34991828

Group type: EXPERIMENTAL
Intervention: Hydra transcatheter aortic valve (THV)
Number of subjects: 157
Study: 34991937

Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitors (PCSK9-I) therapy
Number of subjects: 80
Study: 34992051

Group type: EXPERIMENTAL
Intervention: Use of marijuana
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: Use of alcohol
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: Belief in public health measures
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: Graduate students
Number of subjects: 1997

Group type: EXPERIMENTAL
Intervention: Students with ≥20 roommates
Number of subjects: 1997

Group type: COMPARATOR
Intervention: Mental health status
Number of subjects: 1997

Group type: COMPARATOR
Intervention: Average daily steps (Fitbit)
Number of subjects: 1997
Study: 34992093

Group type: EXPERIMENTAL
Intervention: Andecaliximab monotherapy (800 mg IV Q2W)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Andecaliximab in combination with nivolumab (800 mg IV Q2W)
Number of subjects: 18
Study: 34992101

Group type: EXPERIMENTAL
Intervention: EQ-5D-3L intervention
Number of subjects: 266241

Group type: COMPARATOR
Intervention: General population
Number of subjects: 266241
Study: 34992118

Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (LDN) 4.5 mg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 34992122

Group type: EXPERIMENTAL
Intervention: Postbirth follow-up recommendations compliance
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Risk factors for non-compliance
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Risk factors for unnecessary PED visits
Number of subjects: 249
Study: 34992150

Group type: EXPERIMENTAL
Intervention: Neuraxial anesthesia
Number of subjects: 11523

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 11523
Study: 34992327

Group type: EXPERIMENTAL
Intervention: Heart to Heart training intervention for foster and kinship caregivers
Number of subjects: 0
Study: 34992372

Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Vortioxetine 20 mg
Number of subjects: 489

Group type: COMPARATOR
Intervention: Vortioxetine 10 mg or 20 mg
Number of subjects: 489
Study: 34992380

Group type: EXPERIMENTAL
Intervention: Multidisciplinary vocational rehabilitation program with lifestyle intervention
Number of subjects: 11
Study: 34992575

Group type: EXPERIMENTAL
Intervention: Endovascular treatment during on-hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endovascular treatment during off-hours
Number of subjects: 0
Study: 34992825

Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with camrelizumab, nab-paclitaxel, and carboplatin
Number of subjects: 40
Study: 34992965

Group type: EXPERIMENTAL
Intervention: Caregiver-reported physical aggression
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Caregiver-reported sexual aggression
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of physical aggression at 12 months
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of sexual aggression at 12 months
Number of subjects: 170
Study: 34993171

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 34993216

Group type: EXPERIMENTAL
Intervention: Alterations in the Gut Microbiota
Number of subjects: 0
Study: 34993222

Group type: EXPERIMENTAL
Intervention: Very Low-Carbohydrate High-Fat Diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 34993386

Group type: EXPERIMENTAL
Intervention: Aspirin-sensitive patients
Number of subjects: 128

Group type: COMPARATOR
Intervention: Aspirin-resistant patients
Number of subjects: 128
Study: 34993388

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study: 34993715

Group type: EXPERIMENTAL
Intervention: Single SSPE
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Multiple SSPE
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Incidental SSPE
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Symptomatic SSPE
Number of subjects: 224
Study: 34993850

Group type: EXPERIMENTAL
Intervention: OAGB
Number of subjects: 29

Group type: COMPARATOR
Intervention: RYGB
Number of subjects: 29
Study: 34994093

Group type: EXPERIMENTAL
Intervention: 225 mg of oral testosterone undecanoate (TLANDO) twice a day for 24 days
Number of subjects: 95
Study: 34994094

Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) measurements
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Physical performance tests (grip strength, 6 min walk test)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Rockwood Clinical Frailty Scale (RCFS)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: EuroSCORE II combined with BIA and CT measurements
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Body cell mass derived by BIA
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Muscle area in CT scan (TPA/BSA)
Number of subjects: 94
Study: 34994169

Group type: EXPERIMENTAL
Intervention: Mindful Eating Questionnaire (MEQ)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Distracted eating behavior
Number of subjects: 46

Group type: COMPARATOR
Intervention: Dietary Inflammatory Index (DII)
Number of subjects: 46
Study: 34994234

Group type: EXPERIMENTAL
Intervention: POLARIS stent implantation
Number of subjects: 199
Study: 34994306

Group type: EXPERIMENTAL
Intervention: SSEQ-DK (Stroke Self-Efficacy Questionnaire - Danish version)
Number of subjects: 50
Study: 34994582

Group type: EXPERIMENTAL
Intervention: Perampanel
Number of subjects: 334
Study: 34994617

Group type: EXPERIMENTAL
Intervention: Trastuzumab and Vinorelbine
Number of subjects: 20
Study: 34994777

Group type: EXPERIMENTAL
Intervention: ST266 eye drops, 4 times daily for 28 days
Number of subjects: 12
Study: 34994968

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 34995128

Group type: EXPERIMENTAL
Intervention: Early locoregional therapy (surgery and radiotherapy per standards for nonmetastatic disease)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Continued systemic therapy
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Early locoregional therapy
Number of subjects: 390
Study: 34995204

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I) delivered via telehealth, 4 sessions over 5 weeks
Number of subjects: 49

Group type: COMPARATOR
Intervention: Waitlist control group for 28 weeks
Number of subjects: 49
Study: 34995639

Group type: EXPERIMENTAL
Intervention: CADe A
Number of subjects: 80

Group type: COMPARATOR
Intervention: CADe B
Number of subjects: 80
Study: 34995640

Group type: EXPERIMENTAL
Intervention: EUS-guided choledochoduodenostomy (EUS-CDS) with lumen-apposing metal stent (LAMS)
Number of subjects: 256
Study: 34995719

Group type: EXPERIMENTAL
Intervention: INCRAFT AAA Stent Graft System
Number of subjects: 150
Study: 34995818

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (CS) eye drops monitored with Kali Drop device
Number of subjects: 90
Study: 34996114

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) treatment for 6 weeks in addition to mood stabilizer
Number of subjects: 20

Group type: COMPARATOR
Intervention: [11C]CUMI-101 BPF in bipolar participants
Number of subjects: 20
Study: 34996361

Group type: EXPERIMENTAL
Intervention: Lower and upper middle-income countries (LMIC)
Number of subjects: 9864

Group type: EXPERIMENTAL
Intervention: Upper middle-income countries (UMIC)
Number of subjects: 9864

Group type: EXPERIMENTAL
Intervention: High-income countries (HIC)
Number of subjects: 9864
Study: 34996401

Group type: EXPERIMENTAL
Intervention: NICU acquires MOM (intervention)
Number of subjects: 284

Group type: COMPARATOR
Intervention: mother provides MOM (control)
Number of subjects: 284
Study: 34996465

Group type: EXPERIMENTAL
Intervention: Starting/completing an ILD-related quality improvement project in the previous 2 years
Number of subjects: 27

Group type: COMPARATOR
Intervention: Site-level characteristics or practices
Number of subjects: 27

Group type: COMPARATOR
Intervention: Hospitalization
Number of subjects: 27

Group type: COMPARATOR
Intervention: Death or lung transplant
Number of subjects: 27

Group type: COMPARATOR
Intervention: Death
Number of subjects: 27
Study: 34996516

Group type: EXPERIMENTAL
Intervention: PACK-CXL
Number of subjects: 39

Group type: COMPARATOR
Intervention: Antimicrobial therapy
Number of subjects: 39
Study: 34996784

Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment
Number of subjects: 52018

Group type: EXPERIMENTAL
Intervention: Antithrombotic treatments
Number of subjects: 52018

Group type: EXPERIMENTAL
Intervention: Healthcare Access and Quality indices
Number of subjects: 52018

Group type: EXPERIMENTAL
Intervention: Management of comorbidities and lifestyle factors
Number of subjects: 52018
Study: 34996920

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pegylated interferon (peg-IFN)
Number of subjects: 0
Study: 34997267

Group type: EXPERIMENTAL
Intervention: Oral iron supplementation (55 mg elemental iron from ferrous sulphate, once daily for 3 months)
Number of subjects: 64
Study: 34997268

Group type: EXPERIMENTAL
Intervention: Combined pulmonary fibrosis and emphysema (CPFE)
Number of subjects: 934

Group type: COMPARATOR
Intervention: Idiopathic pulmonary fibrosis (IPF) alone
Number of subjects: 934
Study: 34997316

Group type: EXPERIMENTAL
Intervention: Novel risk-reducing salpingectomy with delayed oophorectomy
Number of subjects: 577

Group type: COMPARATOR
Intervention: Standard risk-reducing salpingo-oophorectomy
Number of subjects: 577
Study: 34997559

Group type: EXPERIMENTAL
Intervention: Microdose ciprofloxacin
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Microdosing combined with microdialysis
Number of subjects: 2
Study: 34997701

Group type: EXPERIMENTAL
Intervention: Odronextamab (320 mg weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Odronextamab (0.5 mg dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Odronextamab (1-10 mg/L) in Raji xenograft tumor mouse model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predicted human pharmacokinetic parameters from monkey data
Number of subjects: 0
Study: 34997825

Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC) 5 g
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC) 10 g
Number of subjects: 22
Study: 34997889

Group type: EXPERIMENTAL
Intervention: Carboplatin/Etoposide/Vincristine (CarbEV)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Cyclophosphamide/Etoposide/Vincristine (CycEV)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Choroid Plexus Papilloma (CPP)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Atypical Choroid Plexus Papilloma (APP)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Choroid Plexus Carcinoma (CPC)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: CPC younger than three years without irradiation
Number of subjects: 158
Study: 34997984

Group type: EXPERIMENTAL
Intervention: Migration with mother
Number of subjects: 1238

Group type: EXPERIMENTAL
Intervention: Migration without mother
Number of subjects: 1238

Group type: COMPARATOR
Intervention: No migration
Number of subjects: 1238
Study: 34998033

Group type: EXPERIMENTAL
Intervention: Daily protein intake (DPI)
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: DPI/kg BW
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: DPI over time
Number of subjects: 1035

Group type: EXPERIMENTAL
Intervention: Sources of protein intake
Number of subjects: 1035
Study: 34998048

Group type: EXPERIMENTAL
Intervention: Regorafenib + Avelumab
Number of subjects: 34
Study: 34998092

Group type: EXPERIMENTAL
Intervention: anti-EGFR ILs-dox
Number of subjects: 3
Study: 34998370

Group type: EXPERIMENTAL
Intervention: NightOwl™ home-monitoring device for sleep apnea
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard evaluation method (CRM)
Number of subjects: 150
Study: 34998377

Group type: EXPERIMENTAL
Intervention: Multiplex PCR test plus autoimmune antibody testing
Number of subjects: 484

Group type: COMPARATOR
Intervention: mNGS plus autoimmune antibody testing
Number of subjects: 484
Study: 34998425

Group type: EXPERIMENTAL
Intervention: Genicular artery embolization
Number of subjects: 58

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 58
Study: 34998471

Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg once every 2 weeks plus apatinib 250 mg once daily for a 28-day cycle
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus apatinib
Number of subjects: 52
Study: 34998605

Group type: EXPERIMENTAL
Intervention: Recombinant quadrivalent influenza vaccine (RIV4)
Number of subjects: 15774

Group type: COMPARATOR
Intervention: Standard-dose quadrivalent inactivated influenza vaccine (SD-IIV4)
Number of subjects: 15774
Study: 34998740

Group type: EXPERIMENTAL
Intervention: AI-ECG at pulmonary valve position
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Optimal combination of AI-ECG outputs from pulmonary and handheld positions
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Weighted logistic regression with l2 regularisation using AI-ECG outputs from pulmonary and handheld positions
Number of subjects: 1050
Study: 34998942

Group type: EXPERIMENTAL
Intervention: Thoracic branched endografting (TBE)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Surgical revascularization (SR-TEVAR)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Comparison of mid-term survival
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cumulative incidence of device-related endoleak
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cumulative incidence of device-related reintervention
Number of subjects: 55
Study: 34999223

Group type: EXPERIMENTAL
Intervention: Leronlimab (PRO 140)
Number of subjects: 0
Study: 34999322

Group type: EXPERIMENTAL
Intervention: Intervention Bariatric Prospective group
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control Prospective group
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control Bariatric Retrospective group
Number of subjects: 61
Study: 34999563

Group type: EXPERIMENTAL
Intervention: COVID-19 outbreak period
Number of subjects: 246

Group type: COMPARATOR
Intervention: Non COVID-19 outbreak period
Number of subjects: 246
Study: 34999590

Group type: EXPERIMENTAL
Intervention: Patient-Reported Outcomes (PROs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implementation of PROs in clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-interventional studies and registries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regulatory consideration of PROs
Number of subjects: 0
Study: 34999659

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination in naive KTRs
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination in previously infected KTRs
Number of subjects: 736

Group type: COMPARATOR
Intervention: Mycophenolate use
Number of subjects: 736

Group type: COMPARATOR
Intervention: Depleting therapy in the past year
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Interferon gamma release assay in naive KTRs
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Interferon gamma release assay in previously infected KTRs
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Vaccination on the waiting list before transplantation
Number of subjects: 736
Study: 34999667

Group type: EXPERIMENTAL
Intervention: HIV-tailored intervention focused on smoking cessation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention-control intervention focused on smoking cessation
Number of subjects: 0
Study: 34999843

Group type: EXPERIMENTAL
Intervention: Sleep disordered breathing (SDB) measured by respiratory event index (REI) and oxygen desaturation index (ODI)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnea (OSA) diagnosis (REI > 5 events per hour)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: SDB
Number of subjects: 192
Study: 35000058

Group type: EXPERIMENTAL
Intervention: BNT162b2-Comirnaty vaccination
Number of subjects: 31
Study: 35000420

Group type: EXPERIMENTAL
Intervention: preCARDIA therapy for 12 or 24 hours
Number of subjects: 30
Study: 35001023

Group type: EXPERIMENTAL
Intervention: ICEBERG score
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: ICEBERG visual representation
Number of subjects: 207
Study: 35001051

Group type: EXPERIMENTAL
Intervention: Nonanimal stabilized hyaluronic acid/dextranomer treatment
Number of subjects: 283
Study: 35001477

Group type: EXPERIMENTAL
Intervention: MiniMed™ 670G system in Auto Mode
Number of subjects: 46
Study: 35001530

Group type: EXPERIMENTAL
Intervention: Door-to-door HIV testing services (HTS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community-wide 'Man-up' campaigns (IR1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Smaller HTS campaigns at work/social places (IR2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Revisits to households with the option of HIV self-testing (HIVST) (IR3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Community hubs offering HTS (after trial completion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) during revisits (IR3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Work/social place campaigns (IR2)
Number of subjects: 0
Study: 35001562

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 2126

Group type: COMPARATOR
Intervention: No beta-blockers (Control)
Number of subjects: 2126
Study: 35002683

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35002791

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine treatment for 12 weeks
Number of subjects: 8
Study: 35002935

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet adherence
Number of subjects: 0
Study: 35002951

Group type: EXPERIMENTAL
Intervention: Diet items and diet score
Number of subjects: 3402

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 3402

Group type: EXPERIMENTAL
Intervention: Walking to school
Number of subjects: 3402
Study: 35003076

Group type: EXPERIMENTAL
Intervention: Cladribine tablets (CladT)
Number of subjects: 0
Study: 35003094

Group type: EXPERIMENTAL
Intervention: Anti-IL1RAP antibody (nadunolimab, CAN04)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-1RAcP targeting
Number of subjects: 0
Study: 35003503

Group type: EXPERIMENTAL
Intervention: Self-Administration of Auricular Acupuncture
Number of subjects: 0
Study: 35004246

Group type: EXPERIMENTAL
Intervention: Augmented reality (AR) navigation-guided localization
Number of subjects: 4
Study: 35004532

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study: 35004718

Group type: EXPERIMENTAL
Intervention: Prescription intervention; details not available
Number of subjects: 0
Study: 35004719

Group type: EXPERIMENTAL
Intervention: Atraumatic Uterine Cervical Traction Device
Number of subjects: 0
Study: 35004914

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 35005158

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine device (LNG-IUD)
Number of subjects: 21
Study: 35005312

Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 5674
Study: 35005359

Group type: EXPERIMENTAL
Intervention: Looking at the needle
Number of subjects: 160

Group type: COMPARATOR
Intervention: Looking away from the needle
Number of subjects: 160
Study: 35005383

Group type: EXPERIMENTAL
Intervention: Skin temperature asymmetry (SkTA) measured using handheld infrared thermometers after cold pressor test (CPT)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cold pressor test (CPT) involving immersion of a single foot in 5°C water for 30 seconds
Number of subjects: 65

Group type: COMPARATOR
Intervention: Healthy volunteers, known nerve injury, and hand fracture groups
Number of subjects: 65
Study: 35005393

Group type: EXPERIMENTAL
Intervention: Preoperative oral methadone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35005411

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy-based bibliotherapy intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35005428

Group type: EXPERIMENTAL
Intervention: Adjuvanted recombinant zoster vaccine (RZV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35005582

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 112
Study: 35005654

Group type: EXPERIMENTAL
Intervention: Telisotuzumab vedotin (Teliso-V) plus nivolumab
Number of subjects: 37
Study: 35005701

Group type: EXPERIMENTAL
Intervention: Cognitive remediation intervention
Number of subjects: 0
Study: 35005777

Group type: COMPARATOR
Intervention: Antifungal treatment (oral or topical)
Number of subjects: 2212

Group type: COMPARATOR
Intervention: Oral drug treatment
Number of subjects: 2212

Group type: COMPARATOR
Intervention: Adverse events (treatment and control groups)
Number of subjects: 2212